Rephonic
Artwork for BioSpace

BioSpace

BioSpace
FDA
Eli Lilly
Novo Nordisk
Clinical Trials
Pfizer
Gene Therapy
Glp-1
China
Sarepta
Johnson & Johnson
Duchenne Muscular Dystrophy
Job Market
Merck
Drug Development
Moderna
Astrazeneca
Artificial Intelligence
Women's Health
Biopharma
Obesity

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.

PublishesTwice weeklyEpisodes272Founded3 years ago
Number of ListenersCategories
Life SciencesScience

Listen to this Podcast

Artwork for BioSpace

Latest Episodes

In this episode of Denatured, you’ll hear from Jennifer McMahon, partner at Seroba and Joey Mason, venture partner at Claret Capital. We dig into how venture debt buys time when equity can’t — and how Europe’s funding gaps, tranching habits and slowe... more

New data for Genmab and AbbVie’s bispecific antibody Epkinly wowed analysts and could set the partners up for an expanded approval in diffuse large B cell lymphoma; deals have flowed steadily this week, including Novartis’ nearly $8 billion bet on mR... more

In this episode of Denatured, you’ll hear from Max Bronstein, CEO of Aviva Strategies and Teresa Barnes, Chief Executive Warrior of PF Warriors. We dig into why U.S. patients are losing access to rare disease trials happening abroad and how the FAIR ... more

Summit Therapeutics scores a $2 billion equity investment from AstraZeneca to support ivonescimab’s late-stage development; uniQure crashes after four-year data from its Huntington’s disease gene therapy failed to impress; Kyverna Therapeutics brings... more

Key Facts

Accepts Guests
Contact Information
Podcast Host
Number of Listeners
Find out how many people listen to this podcast per episode and each month.

Similar Podcasts

People also subscribe to these shows.

Biotech Hangout
Biotech HangoutDaphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler and more
Unhedged
UnhedgedFinancial Times

Recent Guests

Mike Patterson
CEO, North America at Curium
Curium
Episode: How radioligand therapy is rewriting cancer care
Sabine Brookman-May
VP and Head of Global Clinical Development at Curium
Curium
Episode: How radioligand therapy is rewriting cancer care
Philip Jacob Rosenfeld
Professor of Ophthalmology at the University of Miami Health System and Bascom Palmer Eye Institute
Bascom Palmer Eye Institute; University of Miami Health System
Episode: When vision fades: Rethinking wet AMD and the durability gap
Wesley Jackson
Chief Science Officer at Valitor
Valitor
Episode: When vision fades: Rethinking wet AMD and the durability gap
Arvind Singh
VP and Global Head of Supply Chain
SK Pharmteco
Episode: The supply chain fault lines of modern pharma
Christina Takke
Managing Partner at V-Bio Ventures
V-Bio Ventures
Episode: Breaking borders: Building biotech scale in Benelux
Mariette van der Velden-Roesink
Founding Partner at Curie Capital
Curie Capital
Episode: Breaking borders: Building biotech scale in Benelux
Hilary Rosselot
Executive Director
National Fragile X Foundation
Episode: Fragile X at a turning point: Breaking through the clinical bottleneck
Jordi Fàbrega
Co-Founder and CEO
CONNECTA Therapeutics
Episode: Fragile X at a turning point: Breaking through the clinical bottleneck

Hosts

Jennifer Smith-Parker
Host of BioSpace programs and episode introducer/guide, with focus on translating science into business outcomes
Jeff Axt
Host focusing on market-moving biopharma coverage and industry analysis
Heather McKenzie
Senior Editor and host contributing to briefings and roundups

Reviews

4.7 out of 5 stars from 33 ratings
  • informative and lively

    Love the podcast. The roundtable discussions are engaging, informative, and lively. The information shared helps keep me current in the biopharma industry.

    Apple Podcasts
    5
    AudraStar
    United Statesa year ago
  • Great content, the sound quality needs to improve

    The topics discussed are relevant and interesting. The sound quality needs to improve, especially normalizing the volume of the different speakers and using better microphones to avoid saturation.

    Apple Podcasts
    4
    MarcoMtt
    United States2 years ago
  • Love this podcast

    Love this pod, keep up the good work!

    Apple Podcasts
    5
    Ddxbsbabs
    United States2 years ago

Listeners Say

Key themes from listener reviews, highlighting what works and what could be improved about the show.

Informative and lively discussions keep me current in biopharma.
Fans appreciate the content and keep listening.
Sound quality could be improved; volume normalization would help.

Chart Rankings

How this podcast ranks in the Apple Podcasts, Spotify and YouTube charts.

Talking Points

Recent interactions between the hosts and their guests.

When vision fades: Rethinking wet AMD and the durability gap
Q: How does the new delivery approach compare to existing injections in terms of patient experience and monitoring requirements?
The new approach seeks to minimize clinic visits by sustaining therapeutic levels for several months and reducing the need for constant monitoring, while still ensuring fluid control and avoiding inflammation, thereby improving patient quality of life and adherence.
When vision fades: Rethinking wet AMD and the durability gap
Q: What is the core limitation of current anti-VEGF therapies, and what errors is Valitor trying to address?
The main limitation is the need for frequent injections due to the drug's clearance rate; Valitor aims to extend durability by using a hyaluronic acid–based carrier that slows elimination and maintains drug levels longer, enabling a twice-year injection regimen while preserving efficacy and safety.
When vision fades: Rethinking wet AMD and the durability gap
Q: For listeners that are new to AMD, can you describe the condition and how lifestyle and systemic factors influence when and how the disease develops?
Philanthropically, AMD starts as dry degeneration and can progress to the wet form; smoking, cardiovascular health, and obesity accelerate progression, while a diet rich in leafy greens and vigilant systemic health can help slow progression. Wet AMD involves new vessel growth driven by VEGF, causing rapid vision loss unless treated with injections; the eye can be kept in the dry phase with anti-VEGF therapy, but ongoing monitoring and healthy lifestyle choices remain critical.
Breaking borders: Building biotech scale in Benelux
Q: So in a sense of looking for that right pot of money, is there a select pot of money, or is there a limited first pot of money that founders could access?
Early-stage funding is scarce; founders should focus on building a regional syndicate with investors who are active in their geographic area and can connect to others to scale the funding chain.
Fragile X at a turning point: Breaking through the clinical bottleneck
Q: What would constitute a successful outcome for the Fragile X field in the coming years?
A successful outcome includes the first approved therapy that meaningfully improves functioning and independence, along with the development of more reliable biomarkers, better endpoints, and a sustainable trial ecosystem that supports multiple therapies. Even if the first drug isn't a complete solution, it should validate the field and catalyze ongoing progress.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Listeners per Episode
Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About BioSpace

What is BioSpace about and what kind of topics does it cover?

The show consistently covers the business side of life sciences, with a focus on biopharma funding, corporate partnerships, regulatory dynamics, and market-moving developments. Episodes span from regional ecosystem building in Europe (notably Italy and the Nordic region) to big-picture industry moves like mergers, IPOs, and leadership changes at major companies. A recurring strength is bringing together investors, executives, and editors to dissect strategy, finance, and commercialization, often with practical takeaways for founders and sponsors. Notable strengths include a strong emphasis on translational science, corporate venture perspectives, and how policy and regulatory signals shape investment and development timelines. The format te... more

Where can I find podcast stats for BioSpace?

Rephonic provides a wide range of podcast stats for BioSpace. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to BioSpace and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does BioSpace get?

Rephonic provides a full set of podcast information for four million podcasts, including the number of listeners. View further listenership figures for BioSpace, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for BioSpace?

Rephonic provides comprehensive predictive audience data for BioSpace, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does BioSpace have?

To see how many followers or subscribers BioSpace has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

Which podcasts are similar to BioSpace?

These podcasts share a similar audience with BioSpace:

1. BioCentury This Week
2. The Readout Loud
3. Biotech Hangout
4. The Long Run with Luke Timmerman
5. Unhedged

How many episodes of BioSpace are there?

BioSpace launched 3 years ago and published 272 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact BioSpace?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for BioSpace?

Rephonic pulls ratings and reviews for BioSpace from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for BioSpace?

Rephonic provides full transcripts for episodes of BioSpace. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on BioSpace?

Recent guests on BioSpace include:

1. Mike Patterson
2. Sabine Brookman-May
3. Philip Jacob Rosenfeld
4. Wesley Jackson
5. Arvind Singh
6. Christina Takke
7. Mariette van der Velden-Roesink
8. Hilary Rosselot

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.
Try it free for 7 days